Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Opthea Limited

A Comparative Analysis of SG&A Expenses: Bristol-Myers Squibb vs. Opthea Limited

In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Bristol-Myers Squibb Company and Opthea Limited, from 2014 to 2023.

Bristol-Myers Squibb, a giant in the sector, consistently reported SG&A expenses averaging around $6 billion annually. Notably, their expenses surged by approximately 60% from 2019 to 2020, reflecting strategic investments or market expansions. In contrast, Opthea Limited, a smaller entity, exhibited a more volatile trend, with expenses peaking in 2023 at nearly $42 million, a staggering 1,500% increase from 2014.

This stark contrast highlights the differing scales and strategies of these companies, offering insights into their operational priorities and market positioning. Missing data for 2024 suggests ongoing developments worth monitoring.